What are CTLA-4 inhibitor drugs?

CTLA-4 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CTLA-4). 1 are currently marketed, with 8 more in clinical development.

What are the marketed CTLA-4 inhibitor drugs?

Marketed CTLA-4 inhibitor drugs include tremelimumab (treme).

CTLA-4 inhibitor

1 marketed 6 in Phase 3 2 in Phase 2

This page covers all CTLA-4 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CTLA-4.

Targets

CTLA-4

Marketed (1)

tremelimumab (treme) · AstraZeneca · Oncology
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.

Phase 3 pipeline (6)

EU-sourced YERVOY® · Shanghai Henlius Biotech · Oncology
YERVOY (ipilimumab) blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Ipilimumab infusion · The Netherlands Cancer Institute · Oncology
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Tremelimumab (Regimen 2) · AstraZeneca · Oncology
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Tremelimumab (Regimen 1) · AstraZeneca · Oncology
Tremelimumab is a monoclonal antibody that targets CTLA-4, a protein that helps regulate the immune system.
RANCAD · TSH Biopharm Corporation Limited · Oncology
RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses.
Ipilimumab Injection · Federation Francophone de Cancerologie Digestive · Oncology
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.

Phase 2 pipeline (2)

HF10 plus Ipilimumab · Takara Bio Inc. · Oncology
HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells.
INCMGA00012 · Providence Health & Services · Oncology
INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity.